1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

13 Principles of Effective Addictions Treatment
It’s about time Tackling substance misuse in older people.
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Scottish Prisons and the Hepatitis C Challenge Scottish Drugs Forum February 2007 Andrew Fraser.
 Centre for Drug Misuse Research Glasgow Scotland From Harm Reduction to Abstinence: A Journey in Drug Treatment Pol From Harm Reduction to Abstinence:
SUD Module C: Care Management. or……. How to not cure anyone & still accomplish something & go home happy.
Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.
Treatment Of Medical, Psychiatric, and Substance Use Co-morbidities In People Infected With HIV Who Use Drugs Frederick L. Altice (US, Malaysia, Ukraine)
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Treatment of HCV infection among active IDUs Jason Grebely, PhD Lecturer Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology.
Alcoholism and Substance Abuse. Focus Alcoholism.
Alcohol Interventions: What the research tells us Professor Colin Drummond.
The Dual Diagnosis Practitioner Role in an Assertive Outreach Team Patrick Goodwin and Craig Sherrock Dual Diagnosis Practitioners.
The Contribution of Mental Health Services to Tackling Health Inequalities Dr Alastair Cook Chair RCPsych in Scotland.
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
A Social Marketing Approach to the ‘wicked’ problem of alcohol Newcastle upon Tyne North Tyneside Northumberland Lynda Seery Public Health Lead for Substance.
Addiction Treatment Works! Through Collaboration and Problem Solving amongst all disciplines.
Treating Hepatitis C in Methadone Patients: With Planning, it Works! Patricia Perkins, MS, MPH Independent Healthcare Consultant Community Advisory Board.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Nelson Alcohol and Other Drug Service Nelson Alcohol and Other Drug Service GP CME Presentation March 2009.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
SLIDE 1 of 34 IS THERE A CAUSAL RELATIONSHIP BETWEEN SUBSTANCE ABUSE AND PSYCHIATRIC ILLNESS? Dr Martin Frisher Department of Medicines Management Keele.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Good Prescribing to support Criminal Justice Interventions
OPIOID SUBSTITUTION THERAPY
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Clinical Research in the Addiction Service: The Lows and the Highs Feb 2011 Dr Bobby Smyth.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Alcohol. Plan Role play in small groups Discuss any issues which arise Go through some of the basics Cover the entire “journey”
MRCPsych addiction psychiatry seminar series Policy, guidance, service structures and legal framework of addiction treatment Epidemiology of addictive.
Hepatitis C When, how and which patients should be treated Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.
Pennsylvania: The State of HCV 2015
Ph: Disclaimer: Information on this page is not a substitute for medical consultation.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
1 December 8, 2015 Crista M. Taylor, LCSW-C Director, Information, Planning and Development Adrienne Breidenstine, MSW Director of Opioid Overdose Prevention.
Jennifer R. Havens, PhD, MPH Associate Professor
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
S L I D E 0 Enhanced Uptake of Hepatitis C Treatment in an Opioid Treatment Program in the Direct Acting Antiviral Era Jenna Butner MD 1,2, Julia Shi MD.
“Measuring the Units” Alcohol liaison services (ALS) Louise Poley Consultant Nurse in Substance Misuse Cardiff and Vale University Health Board.
MRCPsych addiction psychiatry seminar series Policy, guidance and legal framework of addiction treatment Classification of substance use disorders Assessment.
Hep C clinic Jessie Anderson, Cathy Scott, Kim Macbeth, Dave Findlay and John Budd Edinburgh Access Practice.
Evidence-based practice guidelines: Chronic harms of substance use.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
What is the contribution of alcohol to liver disease in the hepatitis C infected population. The epidemiological evidence Hamish Innes Research Fellow.
Alcohol dependence and harmful alcohol use NICE quality standard August 2011.
Medication Assisted Treatment for Opioid Use Disorders
Specialist service provision. Who is involved in specialist services? Statutory services –Run by NHS and Social Care, these deliver medical and psychosocial.
Substance Exposed Newborns: Addressing Substance Use Disorder
The changing landscape of hepatitis infection
Opioids Aware A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.
CRISIS RESOLUTION / HOME TREATMENT - DEFINITION
Medication-Assisted Therapy at Coleman Profession Services
Cascade of care for persons newly diagnosed
Integrating Hepatitis C Treatment in Primary Care
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
MENTAL HEALTH and SUBSTANCE MISUSE
Treatments for Addiction
‘I’m not a lone soldier’ – A multi-disciplinary response to the management and treatment of benzodiazepine use within the general practitioner setting.
Professor Jack Lambert
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Hepatitis C Testing, Treatment, Care and Support
Presentation transcript:

1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for drug prescribing services? Scottish Drugs Forum 28th Feb 2007

2 What are the challenges for the service user? Accessibility Engagement Retention in treatment Effective outcome for service user and clinician subjectively as well as objectively

Royal College of General Practitioners (Scotland)

8 Not so Surprising News! For many current IDVU’s there are multiple contraindications to therapy.

9 Clinical Guidelines on the management of Hepatitis C Booth et al GUT 2001 Some patients on oral methadone and particularly those individuals who are committed to rehabilitation programmes may be considered for treatment

10 Clinical Guidelines on the management of Hepatitis C Booth et al GUT 2001 Or is that MAYBE?

11 Surprising News! Studies have shown that IDU’s current, former and relapsing do just as well in treatment for HCV as non users. This is in terms of: Retention in treatment. Clearance of the virus. (Also low rates of subsequent reinfection)

12 Here are some of them! Backmund M, Meyer K et al Hepatology 2001 Cournot M, Gilbert A, et al Gastroenterology Clin Biol 2004 Dalgard O, Bjoro K, et al Eur Addict Res 2002 ( 5 years follow up )

13 Here are some more of them! Interferon alpha therapy for hepatitis C: Treatment completion and response rates among patients with substance use disorders. Substance Abuse treatment, Prevention and Policy ( U.S.) Published 12/01/2007

14 There are no drug services currently integrated with hepatology/gastroenterology clinics. But we have some managed clinical networks We do have plans to look at this: Hepatitis C Action Plan for Scotland_ The Testing, Treatment Care and Support Working Group are well aware of the changing view of treating IDU infected with HCV- Needs Assessment is being carried out

15 Coal face Issues Service users may be using for 1 to 4 years before presentation: Issues for education ( Probably need to start at the primary school) Issues for NDX Issues for outreach.

16 Coal face Issues Alcohol primary and secondary Co-morbidity.

17 Coal face Issues Where are the rest of the 50,000? Who is best placed to: identify? engage? test? treat- managed clinical network

18 Case Study 1 Female patient born Jan 1971 Fairly typical history of drug misuse starting early teens Little alcohol involved initially mainly cannabis, “recreational” drugs, benzodiazepines and opioids 1 st IV use aged 18 Various interventions from 22 when first attended specialist service. First substantial period of abstinence from 25 years to 28 years of age on methadone prescription

19 Case Study 1 28 years of age alcohol “social drinking” pubs only 31 problematic drinking at home usually vodka. Average consumption 1 litre / day vodka. 32 required “eye opener” 33 ( Jan 2004) first alcohol detox. Residential ( suspicion of previous convulsion related to benzodiazepine/alcohol withdrawal) Rapid relapse to alcohol, became jaundiced, admitted medical ward( May 2004), presence of alcoholic liver disease and oesophageal varices noted.HCV diagnosed.

20 Case Study 1 May to Nov 2004 continued illicit drug free but return to alcohol.Approxiamtely half to whole bottle vodka daily. Methadone reduced to 55mgs daily by this time. 19 th November 2004 re-referred to medical clinic deeply jaundiced. Diagnosis alcohol related cirrhosis. 26 th Nov 2004 died.

21 Case Study 2 Female patient born 1972 Problematic alcohol use at 12 years of age Daily alcohol use to intoxication several days a week at 14 years Alcohol dependency 16 years use of benzodiazepines and buprenorphine 18 First IV use of buprenorphine 19 First IV use of heroin

22 Case Study 2 Female patient born reasonable period of abstinence on methadone 28 to 33 unstable, in and out of methadone treatment 33 Returned to full engagement with services, methadone dose max. 110 mgs currently on 80 mgs Past 2 years alcohol more and more of a problem This year in patient alcohol detox. Relapsed and currently waiting for urgent reassessment ( to-morrow) With view to further detox.

23 Case Study 2 Female patient born 1972 Recent admission to medical ward. GI bleed.(still awaiting more results) HCV diagnosed PCR positive. Liver function tests disturbed alcohol/HCV Management! Prognosis?